الفهرس 
Therapeutic potentiality of 2epigallocatchin-3-gallate3 and/or paclitaxel in targeting cancer stem cells (CSCs) in mammary gland
AbstractOnly 14 pages are availabe for public view
 |  | from | 136 |  |  |
| | | from | 136 | | |
Abstract
Cancer stem cells (CSCs) are a subpopulation of tumor cells that own self-renewal capability, tumor recurrence and metastasis as well as resistance to current cancer therapies. Epigallocatechin-3-gallate (EGCG) is a type of catechin found in green tea that is known by its powerful chemoprotective ability. Hence, the current study aimed to focus on the effect of EGCG on 7,12 dimethyl-benzanthracene (DMBA)-induced tumor metastasis, angiogenesis and CSCs. For these reasons both in vitro and in vivo studies were carried out. The in vitro evaluation of the effect of the used chemicals (paclitaxel, EGCG and their combination) at different doses on one of the breast cancer cell line, MCF-7 was carried out to evaluate the cell viability and apoptosis. The highest significant alterations in cellular morphology were observed on the sole use of EGCG followed by combined use of both paclitaxel and EGCG, while the use of paclitaxel alone showed the least effect. It was observed that the later cellular alterations were dose related. In vivo studies, therapy was started in 3 groups of DMBA-induced mammary cancer in virgin female rats using EGCG, paclitaxel or their combination. It was found that EGCG exhibited significant chemopreventive effects and anti-CSCs activity through several pathways including significant decrease in the size and number of tumors/ rat, significant amelioration of the oxidative stress markers{u2019} alterations as well as significant inhibition of CD44, VEGF, Ki-67 and MMP-2 expression associated with significant increased expression of caspase-3. In addition, the combination of EGCG to paclitaxel significantly enhanced the later anticancer efficacy. Herein it is concluded that EGCG could be offered as an unprecedented curative strategy to eradicate cancer